SIGNIFICANCE STATEMENT: Although cytomegalovirus (CMV) infection is an important factor in the pathogenesis of kidney allograft rejection, previous studies have not determined the optimal CMV prevention strategy to avoid indirect effects of the virus. In this randomized trial involving 140 kidney transplant recipients, incidence of acute rejection at 12 months was not lower with valganciclovir prophylaxis (for at least 3 months) compared with preemptive therapy initiated after detection of CMV DNA in whole blood. However, prophylaxis was associated with a lower risk of subclinical rejection at 3 months. Although both regimens were effective in preventing CMV disease, the incidence of CMV DNAemia (including episodes with higher viral loads) was significantly higher with preemptive therapy. Further research with long-term follow-up is warranted to better compare the two approaches. BACKGROUND: The optimal regimen for preventing cytomegalovirus (CMV) infection in kidney transplant recipients, primarily in reducing indirect CMV effects, has not been defined. METHODS: This open-label, single-center, randomized clinical trial of valganciclovir prophylaxis versus preemptive therapy included kidney transplant recipients recruited between June 2013 and May 2018. After excluding CMV-seronegative recipients with transplants from seronegative donors, we randomized 140 participants 1:1 to receive valganciclovir prophylaxis (900 mg, daily for 3 or 6 months for CMV-seronegative recipients who received a kidney from a CMV-seropositive donor) or preemptive therapy (valganciclovir, 900 mg, twice daily) that was initiated after detection of CMV DNA in whole blood (≥1000 IU/ml) and stopped after two consecutive negative tests (preemptive therapy patients received weekly CMV PCR tests for 4 months). The primary outcome was the incidence of biopsy-confirmed acute rejection at 12 months. Key secondary outcomes included subclinical rejection, CMV disease and DNAemia, and neutropenia. RESULTS: The incidence of acute rejection was lower with valganciclovir prophylaxis than with preemptive therapy (13%, 9/70 versus 23%, 16/70), but the difference was not statistically significant. Subclinical rejection at 3 months was lower in the prophylaxis group (13% versus 29%, P = 0.027). Both regimens prevented CMV disease (in 4% of patients in both groups). Compared with prophylaxis, preemptive therapy resulted in significantly higher rates of CMV DNAemia (44% versus 75%, P < 0.001) and a higher proportion of patients experiencing episodes with higher viral load (≥2000 IU/ml), but significantly lower valganciclovir exposure and neutropenia. CONCLUSION: Among kidney transplant recipients, the use of valganciclovir prophylaxis did not result in a significantly lower incidence of acute rejection compared with the use of preemptive therapy. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Optimizing Valganciclovir Efficacy in Renal Transplantation (OVERT Study), ACTRN12613000554763 .

Biomedical Centre Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Hematology and Oncology Faculty of Medicine in Pilsen Charles University and Teaching Hospital Pilsen Czech Republic

Department of Immunology and Allergology Faculty of Medicine in Pilsen Charles University and Teaching Hospital Pilsen Czech Republic

Department of Internal Medicine 1 Faculty of Medicine in Pilsen Charles University and Teaching Hospital Pilsen Czech Republic

Department of Molecular Genetic Biopticka laboratory Pilsen Czech Republic

Department of Pathology Faculty of Medicine in Pilsen Charles University and Teaching Hospital Pilsen Czech Republic

Division of Information Technologies and Statistics Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Zobrazit více v PubMed

Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–931. doi:10.1097/tp.0000000000002191 PubMed DOI

L'Huillier AG, Ferreira VH, Ku T, Bahinskaya I, Kumar D, Humar A. Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients. Am J Transplant. 2019;19(9):2495–2504. doi:10.1111/ajt.15371 PubMed DOI

Courivaud C, Bamoulid J, Chalopin JM, Gaiffe E, Tiberghien P, Saas P. Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients. J Infect Dis. 2013;207(10):1569–1575. doi:10.1093/infdis/jit064 PubMed DOI

Belga S, MacDonald C, Chiang D, Kabbani D, Shojai S, Abraldes JG. Donor graft cytomegalovirus serostatus and the risk of arterial and venous thrombotic events in seronegative recipients after non-thoracic solid organ transplantation. Clin Infect Dis. 2021;72(5):845–852. doi:10.1093/cid/ciaa125 PubMed DOI

Reischig T, Jindra P, Svecova M, Kormunda S, Opatrny K, Jr., Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol. 2006;36(2):146–151. doi:10.1016/j.jcv.2006.01.015 PubMed DOI

Bachelet T, Couzi L, Pitard V, Sicard X, Rigothier C, Lepreux S. Cytomegalovirus-responsive gammadelta T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions. J Am Soc Nephrol. 2014;25(11):2471–2482. doi:10.1681/ASN.2013101052 PubMed DOI PMC

Loupy A, Lefaucheur C. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018;379(12):1150–1160. doi:10.1056/NEJMra1802677 PubMed DOI

Rampersad C, Balshaw R, Gibson IW, Ho J, Shaw J, Karpinski M. The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. Am J Transplant. 2022;22(3):761–771. doi:10.1111/ajt.16883 PubMed DOI PMC

Leeaphorn N, Garg N, Thamcharoen N, Khankin EV, Cardarelli F, Pavlakis M. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: a paired kidney analysis. Am J Transplant. 2019;19(2):573–584. doi:10.1111/ajt.15183 PubMed DOI

Reischig T, Kacer M, Hruba P, Jindra P, Hes O, Lysak D. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation. Antivir Ther. 2017;22(6):503–513. doi:10.3851/IMP3129 PubMed DOI

Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10(5):1228–1237. doi:10.1111/j.1600-6143.2010.03074.x PubMed DOI

Reischig T, Kacer M, Jindra P, Hes O, Lysak D, Bouda M. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin J Am Soc Nephrol. 2015;10(2):294–304. doi:10.2215/CJN.07020714 PubMed DOI PMC

Reischig T, Kacer M, Hruba P, Hermanova H, Hes O, Lysak D. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial. BMC Infect Dis. 2018;18(1):573. doi:10.1186/s12879-018-3493-y PubMed DOI PMC

Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8(1):69–77. doi:10.1111/j.1600-6143.2007.02031.x PubMed DOI

Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2012;23(9):1588–1597. doi:10.1681/ASN.2012010100 PubMed DOI PMC

Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8(5):975–983. doi:10.1111/j.1600-6143.2007.02133.x PubMed DOI

Witzke O, Nitschke M, Bartels M, Wolters H, Wolf G, Reinke P. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial. Transplantation. 2018;102(5):876–882. doi:10.1097/tp.0000000000002024 PubMed DOI

Limaye AP, Green ML, Edmison BC, Stevens-Ayers T, Chatterton-Kirchmeier S, Geballe AP. Prospective assessment of cytomegalovirus immunity in high-risk donor-seropositive/recipient-seronegative liver transplant recipients receiving either preemptive therapy or antiviral prophylaxis. J Infect Dis. 2019;220(5):752–760. doi:10.1093/infdis/jiz181 PubMed DOI PMC

Florescu DF, Qiu F, Schmidt CM, Kalil AC. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis. 2014;58(6):785–803. doi:10.1093/cid/cit945 PubMed DOI

Dube GK, Morris HK, Crew RJ, Pereira MR, Cohen DJ, Mohan S. Febrile neutropenia after kidney transplantation. Am J Transplant. 2021;21(10):3436–3443. doi:10.1111/ajt.16714 PubMed DOI

Fisher CE, Knudsen JL, Lease ED, Jerome KR, Rakita RM, Boeckh M. Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients. Clin Infect Dis. 2017;65(1):57–63. doi:10.1093/cid/cix259 PubMed DOI PMC

Boivin G, Goyette N, Farhan M, Ives J, Elston R. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol. 2012;53(3):208–213. doi:10.1016/j.jcv.2011.12.019 PubMed DOI

Couzi L, Helou S, Bachelet T, Moreau K, Martin S, Morel D. High incidence of anticytomegalovirus drug resistance Among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant. 2012;12(1):202–209. doi:10.1111/j.1600-6143.2011.03766.x PubMed DOI

Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6(9):2134–2143. doi:10.1111/j.1600-6143.2006.01413.x PubMed DOI

Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20(9):2318–2331. doi:10.1111/ajt.15898 PubMed DOI PMC

Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87–91. doi:10.1093/cid/ciw668 PubMed DOI

Reischig T, Kacer M, Hes O, Machova J, Nemcova J, Lysak D. Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. Am J Transplant. 2019;19(9):2457–2467. doi:10.1111/ajt.15507 PubMed DOI

Reischig T, Kacer M, Hes O, Machova J, Nemcova J, Kormunda S. Viral load and duration of BK polyomavirus viraemia determine renal graft fibrosis progression: histologic evaluation of late protocol biopsies. Nephrol Dial Transplant. 2019;34(11):1970–1978. doi:10.1093/ndt/gfz061 PubMed DOI

Nickeleit V, Singh HK, Dadhania D, Cornea V, El-Husseini A, Castellanos A. The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: a multicenter validation study in the modern era. Am J Transplant. 2021;21(2):669–680. doi:10.1111/ajt.16189 PubMed DOI PMC

Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420–1426. doi:10.1093/cid/ciy696 PubMed DOI PMC

Chevillotte M, von Einem J, Meier BM, Lin FM, Kestler HA, Mertens T. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antivir Res. 2010;85(2):318–327. doi:10.1016/j.antiviral.2009.10.004 PubMed DOI

Korber N, Behrends U, Hapfelmeier A, Protzer U, Bauer T. Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring. J Transl Med. 2016;14(1):175. doi:10.1186/s12967-016-0932-7 PubMed DOI PMC

Reischig T, Kacer M, Vlas T, Drenko P, Kielberger L, Machova J. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic. Am J Transplant. 2022;22(3):801–812. doi:10.1111/ajt.16902 PubMed DOI PMC

Dzabic M, Rahbar A, Yaiw KC, Naghibi M, Religa P, Fellstrom B. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis. 2011;53(10):969–976. doi:10.1093/cid/cir619 PubMed DOI

Heutinck KM, Yong SL, Tonneijck L, van den Heuvel H, van der Weerd NC, van der Pant KA. Virus-specific CD8(+) T cells cross-reactive to donor-alloantigen are transiently present in the circulation of kidney transplant recipients infected with CMV and/or EBV. Am J Transplant. 2016;16(5):1480–1491. doi:10.1111/ajt.13618 PubMed DOI

Callemeyn J, Senev A, Coemans M, Lerut E, Sprangers B, Kuypers D. Missing self-induced microvascular rejection of kidney allografts: a population-based study. J Am Soc Nephrol. 2021;32(8):2070–2082. doi:10.1681/ASN.2020111558 PubMed DOI PMC

Reischig T, Prucha M, Sedlackova L, Lysak D, Jindra P, Bouda M. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. Antivir Ther. 2011;16(8):1227–1235. doi:10.3851/imp1879 PubMed DOI

Singh N, Limaye AP. Preemptive therapy vs antiviral prophylaxis in cytomegalovirus-seronegative liver transplant recipients with seropositive donors-reply. JAMA. 2020;324(11):1108–1109. doi:10.1001/jama.2020.11865 PubMed DOI

El Ters M, Grande JP, Keddis MT, Rodrigo E, Chopra B, Dean PG. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant. 2013;13(9):2334–2341. doi:10.1111/ajt.12370 PubMed DOI

Garcia-Carro C, Dorje C, Asberg A, Midtvedt K, Scott H, Reinholt FP. Inflammation in early kidney allograft surveillance biopsies with and without associated tubulointerstitial chronic damage as a predictor of fibrosis progression and development of de novo donor specific antibodies. Transplantation. 2017;101(6):1410–1415. doi:10.1097/tp.0000000000001216 PubMed DOI

Kaminski H, Couzi L, Garrigue I, Moreau JF, Dechanet-Merville J, Merville P. Easier control of late-onset cytomegalovirus disease following universal prophylaxis through an early antiviral immune response in donor-positive, recipient-negative kidney transplants. Am J Transplant. 2016;16(8):2384–2394. doi:10.1111/ajt.13781 PubMed DOI

Kumar D, Mian M, Singer L, Humar A. An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant. 2017;17(9):2468–2473. doi:10.1111/ajt.14347 PubMed DOI

Natori Y, Alghamdi A, Tazari M, Miller V, Husain S, Komatsu T. Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(4):617–631. doi:10.1093/cid/cix793 PubMed DOI

Jarque M, Crespo E, Melilli E, Gutierrez A, Moreso F, Guirado L. Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: a prospective, interventional, multicenter clinical trial. Clin Infect Dis. 2020;71(9):2375–2385. doi:10.1093/cid/ciz1209 PubMed DOI

Paez-Vega A, Gutierrez-Gutierrez B, Aguera ML, Facundo C, Redondo-Pachon D, Suner M. Immunoguided discontinuation of prophylaxis for cytomegalovirus disease in kidney transplant recipients treated with antithymocyte globulin: a randomized clinical trial. Clin Infect Dis. 2022;74(5):757–765. doi:10.1093/cid/ciab574 PubMed DOI

Schachtner T, Stein M, Babel N, Reinke P. The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication. Am J Transplant. 2015;15(8):2159–2169. doi:10.1111/ajt.13252 PubMed DOI

Stachel D, Stevens-Ayers T, Boeckh M. In vitro studies of the impact of maribavir on CMV-specific cellular immune responses. J Clin Virol. 2016;75:53–59. doi:10.1016/j.jcv.2015.12.012 PubMed DOI

Kumar D, Chin-Hong P, Kayler L, Wojciechowski D, Limaye AP, Osama Gaber A. A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. Am J Transplant. 2019;19(9):2505–2516. doi:10.1111/ajt.15315 PubMed DOI

Kaminski H, Marseres G, Yared N, Nokin MJ, Pitard V, Zouine A. mTOR inhibitors prevent CMV infection through the restoration of functional αβ and γδ T cells in kidney transplantation. J Am Soc Nephrol. 2022;33(1):121–137. doi:10.1681/ASN.2020121753 PubMed DOI PMC

Lentine KL, Smith JM, Hart A, Miller J, Skeans MA, Larkin L. OPTN/SRTR 2020 annual data report: kidney. Am J Transplant. 2022;22(suppl 2):21–136. doi:10.1111/ajt.16982 PubMed DOI

Zobrazit více v PubMed

ANZCTR
ACTRN12613000554763